The Medical Advisor

OneDayMD • The Medical Advisor A single starting point for exploring OneDayMD's health, wellness, longevity, nutrition, cancer, metabolic medicine, emerging therapies and digital-health research. Quick Answer OneDayMD is an independent health-information and research-synthesis platform covering conventional medicine, integrative health, longevity, nutrition, supplements, metabolic medicine, cancer research, emerging therapies and digital health. This Master Guide is the site's central navigation page: use it to find the right topic hub, then move from a broad guide to the specific evidence, study, therapy, supplement, condition or research question you are investigating. On this page Start Here · Core Health Hubs · Cancer & Oncology · Nutrition & Supplements · Longevity · GLP-1 & Metabolic Health · DMSO ·...

ONE-DAYMD RESOURCE HUB GLP-1 medicines, peptide therapies, emerging incretin drugs and research peptides explained in one evidence-focused library. GLP-1 drugs have moved from a diabetes niche into one of the most important areas of modern metabolic medicine. At the same time, interest has expanded into amylin analogs, GIP/GLP-1 combinations, triple agonists, growth-hormone-related peptides, regenerative peptides and other experimental compounds. This resource hub is designed to help readers distinguish between approved medicines , investigational therapies , and research-use compounds . Evidence, regulatory status and safety should always be evaluated for the specific molecule, indication, dose, route of administration and patient population. Start Here GLP-1 Medicines Next-Generation Incretins Major Peptide Medicines Research Peptides Safety Evidence Directory FAQ Edito...

By Dr. Frank (Dr. Francis Yap) · One Day Media Network · Updated September 29, 2026 · Data current to this date Quick Answer "GLP-1 2.0" is the second wave of obesity medicines built on semaglutide and tirzepatide. It improves on the first wave in five ways: more potency (retatrutide, a triple agonist, averaged 28.3% weight loss at 80 weeks in Lilly's TRIUMPH-1 trial), new mechanisms (amylin and glucagon), easier formats (daily pills already approved; monthly injections in Phase 3), better body composition , and lower prices . As of September 29, 2026, no next-generation injectable is approved yet : retatrutide's FDA filing is planned for Q1 2027 and CagriSema's FDA decision is expected in late 2026. Approved 2.0-era products today are the oral drugs (Wegovy pill, Foundayo) and high-dose Wegovy HD. Disclosure: This article is educational and is not medical advice. One Day Media Network participates in affiliate programs (including The Wellness ...